Summary:

- The article discusses a study that found no negative cognitive effects from long-term use of the HIV drug dolutegravir (DTG) in people living with HIV.
- The study, conducted by researchers at the University of Maryland Baltimore County (UMBC), involved cognitive testing of participants over a 96-week period and found no significant differences in cognitive performance between those taking DTG and those taking other antiretroviral medications.
- The findings suggest that DTG, which is a widely used HIV treatment, does not have the brain-related side effects that had been previously reported in some studies, providing reassurance about the long-term use of this important HIV medication.